The company made the announcement after a new round of research results bolstered the case for the experimental medicine, ...
Investor's Business Daily on MSN
Why Apogee slipped on its Dupixent-rivaling eczema results
Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.
SINGAPORE: At the height of her eczema flare, Ms Chloe Ng struggled to hold a pen or carry a spoon as her fingers were covered in open wounds. For years, she cycled through treatments, including oral ...
Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences (BXLS) as the ...
Apogee Therapeutics advances zumilokibart with a $1.3B Blackstone deal, eyes $82.97 value despite asset risks. Read why APGE ...
Eli Lilly (LLY +4.01%) continues to prove the doubters wrong. Despite fears that the company's shares are overvalued, and that stiff competition in the GLP-1 market will eventuall ...
An ointment cream used to treat eczema and other skin conditions was recalled after it was found to be contaminated with Staphylococcus aureus, the Food and Drug Administration announced May 12.
By Kunal Das May 27 (Reuters) - Apogee Therapeutics on Wednesday posted favorable results from a mid-stage trial of its experimental eczema drug and secured a financing deal worth up to $1.3 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results